These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312 [TBL] [Abstract][Full Text] [Related]
17. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. Ng KP; Jain P; Heer G; Redman V; Chagoury OL; Dowswell G; Greenfield S; Freemantle N; Townend JN; Gill PS; McManus RJ; Ferro CJ Trials; 2014 May; 15():158. PubMed ID: 24886272 [TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Bakris G; Yang YF; Pitt B Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623 [TBL] [Abstract][Full Text] [Related]
19. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Bianchi S; Bigazzi R; Campese VM Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949 [TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease. Oka T; Sakaguchi Y; Hattori K; Asahina Y; Kajimoto S; Doi Y; Kaimori JY; Isaka Y Hypertension; 2022 Mar; 79(3):679-689. PubMed ID: 35026955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]